Common Contracts
2 similar null contracts by MDNA Life Sciences, Inc.
12% CONVERTIBLE PROMISSORY NOTE DUE JUNE 1, 2023MDNA Life Sciences, Inc. • January 30th, 2023 • In vitro & in vivo diagnostic substances • New York
THIS 12% CONVERTIBLE PROMISSORY NOTE is one of a series of duly authorized and validly issued 12% Convertible Promissory Notes of MDNA Life Sciences, Inc., a Delaware corporation (the “Company”), having its principal place of business at 2054 Vista Parkway, Suite 400, West Palm Beach, FL 33411, designated as its 12% Convertible Promissory Notes due June 1, 2023 (this Note, the “Note” and, collectively with the other Notes of such series, the “Notes”).
12% CONVERTIBLE PROMISSORY NOTE DUE __, 2023MDNA Life Sciences, Inc. • April 11th, 2022 • Services-commercial physical & biological research • New York
THIS 12% CONVERTIBLE PROMISSORY NOTE is one of a series of duly authorized and validly issued 12% Convertible Promissory Notes of MDNA Life Sciences, Inc., a Delaware corporation (the “Company”), having its principal place of business at 2054 Vista Parkway, Suite 400, West Palm Beach, FL 33411, designated as its 12% Convertible Promissory Notes due __, 2023 (this Note, the “Note” and, collectively with the other Notes of such series, the “Notes”).
